首页> 外文期刊>Journal of Agricultural and Food Chemistry >4-Methylumbelliferone Inhibits Angiogenesis in Vitro and in Vivo
【24h】

4-Methylumbelliferone Inhibits Angiogenesis in Vitro and in Vivo

机译:4-甲基伞形酮在体内和体外抑制血管生成

获取原文
获取原文并翻译 | 示例
           

摘要

4-Methylumbelliferone (4-MU) is a hyaluronic acid biosynthesis inhibitor with antitumoral and antimetastatic effects. The objective of the present study was to determine the potential of 4-MU as an antiangiogenic compound. To fulfill this aim, cultured endothelial cells were used to perform an array of in vitro assays, as well as two different in vivo angiogenesis assays. This study demonstrates that, in fact, 4-MU behaves as a new inhibitor of both in vitro and in vivo angiogenesis. In vitro, 4-MU affects several key steps of angiogenesis, including endothelial cell proliferation, adhesion, tube formation, and extracellular matrix remodeling. Half-maximal inhibitory concentrations (IC_(50)) values in the proliferation assay were 0.65 ± 0.04 and 0.37 ± 0.03 raM for HMEC and RF-24 endothelial cells, respectively. 4-MU (2 mM) treatment for 24 h induced apoptosis in 13% of HMEC and 5% of RF-24 cells. The number of adherent endothelial cells decreased by >20% after 24 h of treatment with 1 mM 4-MU. Minimal inhibitory concentrations in the tube formation assay were 2 and 0.5 mM 4-MU for HMEC and RF-24, respectively. Matrix metalloproteinase-2 expression was differentially altered upon 4-MU treatment in both tested endothelial cell lines. Taken together, the results suggest that 4-MU may have potential as a new candidate multitargeted bioactive compound for antiangiogenic therapy.
机译:4-甲基伞形酮(4-MU)是具有抗肿瘤和抗转移作用的透明质酸生物合成抑制剂。本研究的目的是确定4-MU作为抗血管生成化合物的潜力。为了实现该目的,将培养的内皮细胞用于进行一系列体外测定以及两种不同的体内血管生成测定。这项研究表明,实际上,4-MU可以作为体内和体外血管生成的新抑制剂。在体外,4-MU影响血管生成的几个关键步骤,包括内皮细胞增殖,粘附,管形成和细胞外基质重塑。 HMEC和RF-24内皮细胞在增殖试验中的最大半数抑制浓度(IC_(50))值分别为0.65±0.04和0.37±0.03 raM。 4-MU(2 mM)处理24小时诱导了13%的HMEC和5%的RF-24细胞凋亡。 1 mM 4-MU处理24小时后,粘附的内皮细胞数量减少了> 20%。对于HMEC和RF-24,在试管形成试验中的最小抑菌浓度分别为2和0.5 mM 4-MU。在两种测试的内皮细胞系中,经4-MU处理后基质金属蛋白酶-2的表达均有差异。两者合计,结果表明4-MU可能有潜力作为抗血管生成治疗的新候选多靶生物活性化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号